Brinsupri vs Grafapex
A plain-English comparison of two oncology drugs that may be accessible via NPP.
Side-by-side
| Brinsupri | Grafapex | |
|---|---|---|
| Generic name | brensocatib | treosulfan |
| Manufacturer | Insmed Incorporated | medac GmbH (US commercial rights: Medexus) |
| Modality | Oral DPP1 inhibitor (once-daily tablet) | Alkylating-agent injection (in combination with fludarabine) |
| Indication | Pulmonology (non-cystic fibrosis bronchiectasis) | Hematology/oncology (transplant conditioning) |
| FDA approval | August 12, 2025 | January 21, 2025 |
When physicians choose Brinsupri
Brinsupri is typically selected when its mechanism and labeled indication fit the disease subtype. It is manufactured by Insmed Incorporated and represents an Oral DPP1 inhibitor (once-daily tablet) option in Pulmonology (non-cystic fibrosis bronchiectasis).
When physicians choose Grafapex
Grafapex is typically selected when its mechanism aligns better with disease sub-type, prior therapy failure, or safety profile. It is manufactured by medac GmbH (US commercial rights: Medexus) and represents an Alkylating-agent injection (in combination with fludarabine) option in Hematology/oncology (transplant conditioning).
Both drugs - access via NPP
Both Brinsupri and Grafapex can be accessed via NPP in most of our covered markets. Choice between them is a clinical decision for the treating physician.
Not medical advice
This comparison is information, not clinical guidance.
Request either drug
Safety, interactions, and handling
Drug interactions: Before dispatch, our clinical team reviews every patient's full medication list against published FDA drug-interaction data. If a significant interaction is identified, we notify the prescribing physician and hold shipment until an alternative dose or timing is confirmed.
Contraindications: This medication is not appropriate for every patient. Refer to the US FDA label for full contraindication list. Patients with active infection, pregnancy, known hypersensitivity, or specific organ-system comorbidities may be excluded. Prescribing-physician judgement applies.
Cold chain and storage: Biologics, monoclonals, and cell/gene therapies require validated cold-chain shipping (2-8°C) with continuous temperature monitoring. On arrival we document temperature logs; out-of-spec shipments are flagged and replaced.
Adverse event reporting: Any adverse event should be reported to both the local national regulator and to Reserve Meds's pharmacovigilance team at [email protected]. We forward serious events to the US manufacturer within 15 days per ICH E2D guidance.
Last medically reviewed: 2026-04-22 by AI Clinical Review Agent (see Trust & Compliance).